Bioavailability Assessment of Transdermal Estradiol Gel 0.1% w/w: Estradiol/INTERMED vs. ESTREVA in Healthy Postmenopausal Women

The primary objective of this clinical trial is to evaluate the **bioavailability** of two transdermal gel preparations containing 0.1% w/w **estradiol** under fasting conditions. The trial compares the Estradiol/INTERMED gel 0.1% w/w (Test) with ESTREVA® 0.1% gel (Comparator) in healthy postmenopausal women. This study is clinically relevant as it aims to determine the absorption and availability of estradiol from these formulations, which is crucial for ensuring effective hormone delivery in postmenopausal women. There are no secondary objectives specified for this trial.

The clinical trial involves a study population consisting exclusively of **female** participants, with an age range categorized as adults. The trial does not include any therapeutic indication, as it is conducted with **healthy volunteers**. The sponsor has not provided information regarding the total number of participants. The selection criteria for the trial population have not been specified, and there are no indications of lifestyle considerations such as diet, physical activity, or habits being relevant to the study. The trial does not involve a vulnerable population, and no specific inclusion or exclusion criteria have been highlighted as significant for this study.

The clinical trial is designed as a **randomized**, open-label, single-dose, two-period crossover study to evaluate the **bioavailability** of two transdermal gel preparations containing 0.1% w/w **estradiol**. The trial will compare the test product, Estradiol/INTERMED gel 0.1% w/w, with the comparator, ESTREVA® 0.1% gel, under fasting conditions in healthy postmenopausal women. The study is monocentric and will be conducted in a single location. The trial is categorized as a Phase 3 study, with an estimated recruitment start date of March 1, 2025, and an estimated end date of May 1, 2025.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive either the test or comparator product in the first period, followed by a washout period, and then crossover to the alternate product in the second period. Each period will involve administration of a single dose of the assigned product under fasting conditions. The primary purpose of these visits is to collect pharmacokinetic data to assess the bioavailability of the estradiol formulations.

The expected length of participant involvement is approximately two months, encompassing the screening, treatment, and follow-up phases. Participants will be required to attend all scheduled visits and comply with study procedures. Conditions that may lead to early termination from the study include non-compliance with the study protocol, adverse events that compromise participant safety, or withdrawal of consent. The end-of-study visit will occur after the completion of the second treatment period, where final assessments will be conducted to ensure participant safety and collect any remaining data.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of this data limits the ability to describe the treatments comprehensively.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to begin recruitment on March 1, 2025, with an estimated end date of May 1, 2025. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology to measure, collect, and analyze these efficacy parameters, adhering to the standards expected in a Phase 3 clinical trial. The trial will utilize validated tools and instruments to ensure the accuracy and reliability of the efficacy assessments. The schedule for these assessments will be aligned with the trial's timeline, ensuring that data is collected at appropriate intervals to evaluate the treatment's impact effectively. The trial's design will ensure that all efficacy assessments are conducted in a manner that is consistent with clinical trial protocols, providing robust data to support the evaluation of the treatment's efficacy.